Results 291 to 300 of about 112,622 (301)
Some of the next articles are maybe not open access.

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Nature Reviews Clinical Oncology, 2018
Alan Ashworth, Christopher J Lord
exaly  

An update on PARP inhibitors—moving to the adjuvant setting

Nature Reviews Clinical Oncology, 2014
Amir Sonnenblick   +2 more
exaly  

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

Nature Reviews Molecular Cell Biology, 2017
Arnab Ray Chaudhuri
exaly  

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

Nature Reviews Clinical Oncology, 2016
Angela George, Susana Banerjee
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah   +2 more
exaly  

Home - About - Disclaimer - Privacy